The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Open accessAbstract
Inactivating mutations of the neurofibromatosis 2 (NF2) gene, NF2, result predominantly in benign neurological tumors, schwannomas and meningiomas, in humans; however, mutations in murine Nf2 lead to a broad spectrum of cancerous tumors. The tumor-suppressive function of the NF2 protein, merlin, a membrane-cytoskeleton linker, remains unclear. Here, we identify the mammalian target of rapamycin complex 1 (mTORC1) as a novel mediator of merlin's tumor suppressor activity. Merlin-deficient human meningioma cells and merlin knockdown arachnoidal cells, the nonneoplastic cell counterparts of meningiomas, exhibit rapamycin-sensitive constitutive mTORC1 activation and increased growth. NF2 patient tumors and Nf2-deficient mouse embryonic fibroblasts demonstrate elevated mTORC1 signaling. Conversely, the exogenous expression of wild-type merlin isoforms, but not a patient-derived L64P mutant, suppresses mTORC1 signaling. Merlin does not regulate mTORC1 via the established mechanism of phosphoinositide 3-kinase-Akt or mitogen-activated protein kinase/extracellular signal-regulated kinase-mediated TSC2 inactivation and may instead regulate TSC/mTOR signaling in a novel fashion. In conclusion, the deregulation of mTORC1 activation underlies the aberrant growth and proliferation of NF2-associated tumors and may restrain the growth of these lesions through negative feedback mechanisms, suggesting that rapamycin in combination with phosphoinositide 3-kinase inhibitors may be therapeutic for NF2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,114
The WHO classification of tumors of the nervous system
Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.3.215 · Cited by 1,547
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Rouleau, G. A., Merel, P., Lutchman, M., Sanson, M., Zucman, J., Marineau, C., Hoang-Xuan, K., Demczuk, S., Desmaze, C., Plougastel, B., et al. (1993) · Nature · doi:10.1038/363515a0 · Cited by 1,420
Trofatter, J. (1993) · Cell · doi:10.1016/0092-8674(93)90406-g · Cited by 1,403
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
ERM proteins and merlin: integrators at the cell cortex
Bretscher, A., Edwards, K., & Fehon, R. G. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm882 · Cited by 1,306
Phosphorylation and Functional Inactivation of TSC2 by Erk
Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
The TSC1–TSC2 complex: a molecular switchboard controlling cell growth
Huang, J., & Manning, B. D. (2008) · Biochemical Journal · doi:10.1042/bj20080281 · Cited by 1,237 · cited 4×
“One line of thought is that the limited malignant potential of TSC-associated tumors is due to the attenuation of Akt signaling (17).”
BackgroundInfluentialSelf-citationPRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Hamaratoglu, F., Willecke, M., Kango-Singh, M., Nolo, R., Hyun, E., Tao, C., Jafar-Nejad, H., & Halder, G. (2006) · Nature Cell Biology · doi:10.1038/ncb1339 · Cited by 767
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
Brunn, G. J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J. C., & Abraham, R. T. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00911.x · Cited by 723
Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization
Counter, C. M., Hahn, W. C., Wei, W., Caddle, S. D., Beijersbergen, R. L., Lansdorp, P. M., Sedivy, J. M., & Weinberg, R. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14723 · Cited by 649
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex
Franz, D. N., Leonard, J., Tudor, C., Chuck, G., Care, M., Sethuraman, G., Dinopoulos, A., Thomas, G., & Crone, K. R. (2006) · Annals of Neurology · doi:10.1002/ana.20784 · Cited by 614
Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas
Ruttledge, M. H., Sarrazin, J., Rangaratnam, S., Phelan, C. M., Twist, E. C., Merel, P., Delattre, O., Thomas, G. D., Nordenskjöld, M., Collins, V. P., et al. (1994) · Nature Genetics · doi:10.1038/ng0294-180 · Cited by 573
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
Zhang, H., Cicchetti, G., Onda, H., Koon, H. B., Asrican, K., Bajraszewski, N., Vazquez, F., Carpenter, C. L., & Kwiatkowski, D. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17222 · Cited by 538
Morrison, H., Sherman, L. S., Legg, J., Banine, F., Isacke, C., Haipek, C. A., Gutmann, D. H., Ponta, H., & Herrlich, P. (2001) · Genes & Development · doi:10.1101/gad.189601 · Cited by 536
Yang, Q., & Guan, K.-L. (2007) · Cell Research · doi:10.1038/cr.2007.64 · Cited by 535
The TSC1-TSC2 Complex Is Required for Proper Activation of mTOR Complex 2
Huang, J., Dibble, C. C., Matsuzaki, M., & Manning, B. D. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00289-08 · Cited by 511
Self-citationManning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 476
Self-citationActivity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning
Cai, S.-L., Tee, A. R., Short, J. D., Bergeron, J. M., Kim, J., Shen, J., Guo, R., Johnson, C. L., Kiguchi, K., & Walker, C. L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507119 · Cited by 359
Tuberous Sclerosis: from Tubers to mTOR
Kwiatkowski, D. J. (2003) · Annals of Human Genetics · doi:10.1046/j.1469-1809.2003.00012.x · Cited by 339
The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho
Lamb, R. F., Roy, C., Diefenbach, T. J., Vinters, H. V., Johnson, M. W., Jay, D. G., & Hall, A. (2000) · Nature Cell Biology · doi:10.1038/35010550 · Cited by 326
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions
Lallemand, D., Curto, M., Saotome, I., Giovannini, M., & McClatchey, A. I. (2003) · Genes & Development · doi:10.1101/gad.1054603 · Cited by 324
S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt
Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M., & Manning, B. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.09.019 · Cited by 308
Self-citationOptimized large-scale production of high titer lentivirus vector pseudotypes
Sena-Esteves, M., Tebbets, J. C., Steffens, S., Crombleholme, T., & Flake, A. W. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.08.017 · Cited by 289
Membrane organization and tumorigenesis—the NF2 tumor suppressor, Merlin
McClatchey, A. I., & Giovannini, M. (2005) · Genes & Development · doi:10.1101/gad.1335605 · Cited by 286
Interdomain binding mediates tumor growth suppression by the NF2 gene product
Sherman, L., Xu, H.-M., Geist, R. T., Saporito-Irwin, S., Howells, N., Ponta, H., Herrlich, P., & Gutmann, D. H. (1997) · Oncogene · doi:10.1038/sj.onc.1201418 · Cited by 230
Okada, T., Lopez-Lago, M., & Giancotti, F. G. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200503165 · Cited by 195
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase
Goncharova, E. A., Goncharov, D. A., Noonan, D. J., & Krymskaya, V. P. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200405130 · Cited by 113
Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function
Surace, E. I., Haipek, C. A., & Gutmann, D. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207142 · Cited by 103
Han, S., Santos, T. M., Puga, A. C., Roy, J., Thiele, E. A., McCollin, M., Stemmer-Rachamimov, A. O., & Ramesh, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3277 · Cited by 83
Self-citationMagicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2
Wiederhold, T., Lee, M., James, M. F., Neujahr, R., Smith, N., Murthy, A. E., Hartwig, J. H., Gusella, J. F., & Ramesh, V. (2004) · Oncogene · doi:10.1038/sj.onc.1208110 · Cited by 78
Self-citationHaddad, L. A., Smith, N., Bowser, M., Niida, Y., Murthy, V., Gonzalez-Agosti, C., & Ramesh, V. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207211200 · Cited by 73
Self-citationNeurofibromatosis 2: loss of merlin's protective spell
Gusella, J. F., Ramesh, V., MacCollin, M., & Jacoby, L. B. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)90016-7 · Cited by 59
Self-citationJames, M. F., Lelke, J. M., MacCollin, M., Plotkin, S. R., Stemmer-Rachamimov, A. O., Ramesh, V., & Gusella, J. F. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.09.002 · Cited by 49
Self-citation
Cited by
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Role of Merlin/NF2 inactivation in tumor biology
Petrilli, A. M., & Fernández-Valle, C. (2016) · Oncogene · doi:10.1038/onc.2015.125 · Cited by 458
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Self-citationMerlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus
Li, W., You, L., Cooper, J., Schiavon, G., Pepe-Caprio, A., Zhou, L., Ishii, R., Giovannini, M., Hanemann, C. O., Long, S. B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.029 · Cited by 321
Molecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
Metadata
- Authors
- James, M. F., Han, S., Polizzano, C., Plotkin, S. R., Manning, B. D., Stemmer-Rachamimov, A. O., Gusella, J. F., & Ramesh, V.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2009-08-01
- Volume
- 29
- Issue
- 15
- Pages
- 4250-4261
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2099727495
- Cited by
- 306
- References
- 46
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.